Off label use of prescription medicines in children in outpatient setting in Estonia is common

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 5, 2011, Pages 474-481

  Lass, Jana ^a,b   Irs, Alar ^a,c   Pisarev, Heti ^a   Leinemann, Triin ^c   Lutsar, Irja ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b TARTU UNIVERSITY CLINICS   (Estonia)

^c State Agency of Medicines   (Estonia)

Author keywords

Children; Off label; Paediatric drug information

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTI ACNE AGENT; ANTIDEPRESSANT AGENT; ANTIPARASITIC AGENT; CETIRIZINE; CHLORHEXIDINE; DERMATOLOGICAL AGENT; DICLOFENAC; DROTAVERINE; ESCITALOPRAM; FUSAFUNGINE; HYDROCORTISONE; HYDROXYCHLOROQUINE; MOMETASONE FUROATE; NORTRIPTYLINE; RESPIRATORY TRACT AGENT; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; TOPICAL AGENT;

ADOLESCENT; AMBULATORY CARE; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; DATA BASE; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG UTILIZATION; ESTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; OUTPATIENT; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD;

AMBULATORY CARE; CHILD; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION REVIEW; ESTONIA; HUMANS; OFF-LABEL USE; PEDIATRICS; PRESCRIPTION DRUGS;

EID: 79955142456     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2125     Document Type: Article

References (25)

1. Grieve J, Tordoff J, Reith D, Norris P. Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol 2005; 59(6): 730-735.
2. EMEA. Updated priority list (revised) for studies into off-patent paediatric medicinal products. Doc. Ref. EMEA/197972/2007. London, June 2007. Available at: [Accessed August/16, 2009].
3. Regulation (EC) No1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. Paediatric regulation. Official Journal of the European Union 2006;18:L378/1. Available at: [Accessed August/16, 2009].
4. Young L, Lawes F, Tordoff J, Norris P, Reith D. Access to prescribing information for paediatric medicines in the USA: post-modernization. Br J Clin Pharmacol 2009; 67(3): 341-346.
5. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003; 17(1): 125-131.
6. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164(9): 552-558.
7. Sturkenboom M, Felisi M, Manfredi C, Neubert A, Cantarutti L, Padula R et al. Paediatric status and off-label use of drugs in children in Italy, United Kingdom and the Netherlands. Pharmaceuticals Policy Law 2009; 11(1): 51-59.
8. BMJ Group. BNF for Children. RPS Publishing:London, 2009.
9. Gunn VL NC. The Harriet Lane Handbook. 16th edn. Mosby:PA, 2002.
10. Thomson Reuters Micromedex 2.0. Available at:, 2009; Accessed [August/16, 2009].
11. Statistics Estonia. Available at: [Accessed May/16, 2009].
12. WHO Collaborating Centre for Drug Statistics Methodology. Available at: [Accessed February/12, 2009].
13. European Agency for the Evaluation of Medicinal products editor. ICH Topic E11 Note for Guidance on Clinical Investigation on Medicinal Products in the Paediatric Population (CMP/ICH/2711/99). EMEA:London, 2000.
14. Lindell-Osuagwu L, Korhonen M, Saano S, Helin-Tanninenà M, Naaranlahtià T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009; 34(3): 277-287.
15. Sturkenboom MCJM, Verhamme K, Nicolosi A, Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. BMJ 2008; 337(a2245): 1-13.
16. Ufer M, Rane A, Karlsson Å, Kimland E, Bergman U. Widespread off-label prescribing of topical but not systemic drugs for 350, 000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol 2003; 58(11): 779-783.
17. Schirm E, Tobi H, de Jong-van den Berg, LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003; 111: 291-295.
18. Bücheler R, Schwab M, Mörike K et al. Off-label prescribing to primary care in Germany: retrospective cohort stuy. BMJ 2002; 324: 1311-1312.
19. Schirm E, Tobi H, van Puijenbroek EP, Monster-Simons MH, de Jong-van den Berg, LTW. Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmacoepidemiol Drug Saf 2004; 13(3): 159-165.
20. Dahshan A, Donovan GK. Severe methemoglobinemia complicating topical benzocaine use during endoscopy in a toddler: a case report and review of the literature. Pediatrics 2006; 117(4): e806-e809.
21. Hutcheson KA. Steroid-induced glaucoma in an infant. J AAPOS 2007; 11(5): 522-523.
22. Phillips C. Risk of systemic toxicity from topical ophthalmic chloramphenicol. Scot Med J 2008; 53(3): 54-55.
23. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349(12): 1157-1167.
24. Bua J, L'Erario I, Barbi E, Marchetti F. When off-label is a good practice: the example of paracetamol and salbutamol. BMJ 2008; 93(6): 546-547.
25. Baiardi P, Ceci A, Felisi M, Cantarutti L, Girotto S, Sturkenboom M et al. In-label and off-label use of respiratory drugs in the Italian paediatric population. Acta Paediatr 2010; 99: 544-549.